ECRONICON OPEN ACCESS

EC ORTHOPAEDICS
Mini Review

Bacterial Osteomyelitis: A Persistent Enemy in Musculoskeletal Health

Bhattacharyya S*

Department of Microbiology, AIIH & PH (All India Institute of Hygiene and Public Health), Kolkata, India

***Corresponding Author:** Bhattacharyya S, Department of Microbiology, AIIH & PH (All India Institute of Hygiene and Public Health), Kolkata, India.

Received: August 25, 2025; **Published:** September 22, 2025

Abstract

Bacterial osteomyelitis, a debilitating infection of the bone, stands as a formidable challenge in modern medicine. Often insidious in its onset and notoriously difficult to eradicate, this condition transcends simple bacterial invasion, representing a complex interplay between microbial virulence, host immunity, and intricate anatomical structures. Despite advancements in diagnostic imaging, surgical techniques, and antimicrobial therapies, osteomyelitis continues to inflict significant morbidity, demanding a multidisciplinary approach and relentless pursuit of innovative solutions.

Keywords: *Bacterial Osteomyelitis; Musculoskeletal Health*

Introduction

At its core, osteomyelitis is basically an inflammatory process in the bone and bone marrow caused by an infecting organism, most commonly bacteria [1]. *Staphylococcus aureus* remains the predominant bacterial pathogen, but a myriad of other bacteria, including coagulase-negative staphylococci, Gram-negative rods, Mycobacteria and anaerobes, can be implicated, particularly in specific clinical contexts like diabetic foot infections or post-traumatic scenarios. The route of infection can be of many types, like hematogenous spread, where bacteria travel through the bloodstream from a distant site of infection to the bone, contiguous spread, where infection extends from adjacent infected soft tissues or joints; or direct inoculation, often following trauma, surgery, or the presence of prosthetic implants. Each pathway presents unique diagnostic and therapeutic complexities.

The unique microenvironment of bone poses significant hurdles to successful treatment. Many bacteria may cause osteomyelitis through binding to extracellular matrix (ECM) proteins via microbial surface components [2]. Bone tissue has a relatively poor blood supply compared to other soft tissues, which limits the effective delivery of systemic antibiotics. Furthermore, bacteria can adhere to bone surfaces and prosthetic materials, forming resilient biofilms [3]. These biofilms are protective matrices that shield bacteria from host immune responses and antibiotic penetration, rendering conventional antimicrobial agents far less effective. The presence of necrotic bone, often seen in chronic osteomyelitis, acts as a perpetual nidus for infection, demanding its surgical removal for any hope of cure.

Diagnosing osteomyelitis is often a clinical tightrope walk. Symptoms can be quite non-specific, ranging from localized pain and swelling to fever and malaise [4]. In chronic cases, the signs may be subtle, manifesting as persistent drainage or a non-healing wound. Radiographic imaging, whilst being very crucial, can be misleading in the early stages. Plain X-rays may not show changes for weeks after infection onset. Computed tomography scan can be a very useful method to detect early osseous erosion and to document the presence of sequestrum, foreign body, or gas formation but generally is less sensitive than other modalities [5]. Magnetic Resonance Imaging (MRI) offers superior soft tissue and bone marrow visualization and is considered the gold standard for early detection. Nuclear medicine scans, such as bone scintigraphy or gallium scans, can also aid in localization [6]. However, the definitive diagnosis almost invariably hinges on microbial isolation from bone biopsy specimens, which guides targeted antimicrobial therapy.

The cornerstone of osteomyelitis treatment is a dual strategy involving prolonged antimicrobial therapy and often aggressive surgical debridement [1]. Antibiotics are typically administered intravenously for several weeks, followed by a prolonged oral course, extending for months. The specific antibiotic regimen is dictated by the identified pathogen and its susceptibility profile. However, surgery is frequently indispensable, especially in cases of chronic osteomyelitis, prosthetic joint infections, or large sequestra (dead bone fragments) [7]. The surgical goal is to remove all infected and devitalized tissue, reduce the bacterial load, and create a vascularized environment conducive to healing. This can range from simple debridement to complex reconstructive procedures, including bone grafting or limb salvage.

Despite these interventions, osteomyelitis carries a high risk of recurrence and significant long-term complications. Chronic osteomyelitis can lead to persistent pain, functional impairment, pathological fractures, and even systemic amyloidosis or squamous cell carcinoma in rare, long-standing cases. In severe, recalcitrant infections, amputation may become the unfortunate last resort to preserve life or alleviate intractable suffering. The psychological and economic burden on patients and healthcare systems is substantial, highlighting the urgent need for more effective strategies.

Looking ahead, the fight against bacterial osteomyelitis necessitates continued innovation. Research into novel antimicrobial agents that are capable of penetrating biofilms and overcoming resistance mechanisms is very important. The development of targeted drug delivery systems, improved biomaterials resistant to bacterial colonization, and host-modulating therapies that augment the immune response are quite promising avenues. Early detection, particularly in high-risk populations like diabetics or patients with vascular insufficiency, is pivotal for preventing progression to chronic, harder-to-treat forms. Public health initiatives promoting judicious antibiotic use are also very important to combat the broader threat of antimicrobial resistance that impacts all infectious diseases, including osteomyelitis.

Tubercular osteomyelitis

Tubercular osteomyelitis accounts for approximately 3-5% of all extrapulmonary TB cases. The most common sites of TB osteomyelitis are the spine, small bones of the hands and feet, femur, and tibia [8]. ZN stain from bone abscess can show AFB.

Conclusion

In conclusion, bacterial osteomyelitis remains a very strong and often underestimated opponent in musculoskeletal health. Its complex pathophysiology, diagnostic challenges, and demanding treatment protocols emphasize the necessity for continued vigilance, robust research, and a collaborative approach among clinicians, scientists, and public health experts. Only through concerted efforts can we hope to mitigate the pervasive impact of this persistent foe and improve outcomes for those afflicted by this challenging bone infection.

Bibliography

1. Momodu II and Savaliya V. "Osteomyelitis". In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2025).
2. Hofstee MI., *et al*. "Current concepts of osteomyelitis from pathologic mechanisms to advanced research methods". *American Journal of Pathology* 190.6 (2020): 1151-1163.
3. Singh S., *et al*. "Explaining osteomyelitis and prosthetic joint infections (PJI) in terms of biofilm - a review". *Malaysian Orthopaedic Journal* 15.2 (2021): 1-8.
4. Osteomyelitis (Bone Infection) (2025).
5. Pineda C., *et al*. "Radiographic imaging in osteomyelitis: the role of plain radiography, computed tomography, ultrasonography, magnetic resonance imaging, and scintigraphy". *Seminars in Plastic Surgery* 23.2 (2009): 80-89.
6. Dobaria DG and Cohen HL. "Osteomyelitis imaging". In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2025).
7. Panteli M and Giannoudis PV. "Chronic osteomyelitis: what the surgeon needs to know". *EFORT Open Reviews* 1.5 (2016): 128-135.
8. Knopp BW., *et al*. "Tuberculosis osteomyelitis as an indolent bone mass". *Cureus* 15.8 (2023): e42849.

Volume 16 Issue 5 May 2025